Ecuador vs United States: Tuberculosis treatment success rate by type
Ecuador
72
in 2023
United States
72
in 2022
Ecuador rank
145th
United States rank
145th
Tuberculosis treatment success rate by type over time
- Ecuador
- United States
How they compare
Ecuador currently reports 72 against 72 in United States, a difference of 0.
The two have swapped places 6 times across 25 shared years of data; in 1995 it was United States ahead.
Ecuador ranks 145th and United States ranks 145th of 194 countries.
United States has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Ecuador | United States | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 48.25 | 79 | 30.75 | United States |
| 2000s | 75.89 | 81.44 | 5.56 | United States |
| 2010s | 75.44 | 79.22 | 3.78 | United States |
| 2020s | 70 | 74 | 4 | United States |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis treatment success rate by type, Ecuador or United States?
- Ecuador, at 72 against 72 in United States as of 2023.
- What is the difference in tuberculosis treatment success rate by type between Ecuador and United States?
- 0, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and United States?
- 25 years are reported by both, from 1995 to 2022.
- How do Ecuador and United States rank globally for tuberculosis treatment success rate by type?
- Ecuador ranks 145th and United States ranks 145th of 194 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Tuberculosis treatment success rate by type. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The treatment success rate refers to the share of people diagnosed with tuberculosis (TB) who were either cured or completed their treatment according to the country’s treatment guidelines.